In fact, treatment of patients with CHIKV with TNF-α antagonists, etanercept and adalimumab, showed promise with good tolerance without the reappearance of the viral infections manifestations (Blettery et al., 2016; Brunier et al., 2016). The gene discussed is TNF; the disease is viral infectious disease.